Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2001 1
2003 1
2004 2
2007 1
2008 3
2009 2
2010 4
2011 8
2012 16
2013 13
2014 18
2015 15
2016 8
2017 4
2018 3
2019 8
2020 16
2021 9
2022 14
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27279321

130 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, Shah R, Gopal MG, Narayana Rao T, Srinivas CR, Bhat R, Shetty N, Manmohan G, Sai Krishna K, Padmaja D, Pratap DV, Garg V, Gupta S, Pandey N, Khopkar U, Montero E, Ramakrishnan MS, Nair P, Ganapathi PC. Krupashankar DS, et al. J Am Acad Dermatol. 2014 Sep;71(3):484-92. doi: 10.1016/j.jaad.2014.01.897. Epub 2014 Apr 2. J Am Acad Dermatol. 2014. PMID: 24703722 Clinical Trial.
Anti-CD6 mAbs for the treatment of psoriasis.
Dogra S, D S, Rajagopalan M. Dogra S, et al. Expert Opin Biol Ther. 2020 Oct;20(10):1215-1222. doi: 10.1080/14712598.2020.1776254. Epub 2020 Jun 9. Expert Opin Biol Ther. 2020. PMID: 32466689 Review.
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
Filgueira LM, Cervantes JB, Lovelle OA, Herrera C, Figueredo C, Caballero JA, Sánchez N, Berrio J, Lorenzo G, Cepeda M, Ramos M, Saavedra D, Añe-Kouri AL, Mazorra Z, Leon K, Crombet T, Caballero A. Filgueira LM, et al. Immunotherapy. 2021 Mar;13(4):289-295. doi: 10.2217/imt-2020-0235. Epub 2021 Jan 5. Immunotherapy. 2021. PMID: 33397150 Free PMC article.
Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
Dogra S, D S K, Budamakuntla L, Srinivas CR, Khopkar U, Gupta S, Shetty N, Pratap DV, Gopal MG, Rao TN, Garg V, Sumathy TK, Saraswat A, Bhat R, Kura M, Pandey N, Shah R, Sai Krishna K, Padmaja D, Manmohan G, M S R, Barve A, Montero E. Dogra S, et al. J Am Acad Dermatol. 2015 Aug;73(2):331-3.e1. doi: 10.1016/j.jaad.2015.03.040. J Am Acad Dermatol. 2015. PMID: 26183983 Clinical Trial. No abstract available.
130 results